Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor cd4 t-cell responses through the PD-1-PD-L1 axis

Zhi Chun Ding, Xiaoyun Lu, Miao Yu, Henrique Lemos, Lei Huang, Phillip Chandler, Kebin Liu, Matthew Walters, Antoni Krasinski, Matthias Mack, Bruce R. Blazar, Andrew L. Mellor, David H. Munn, Gang Zhou

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

In recent years, immune-based therapies have become an increasingly attractive treatment option for patients with cancer. Cancer immunotherapy is often used in combination with conventional chemotherapy for synergistic effects. The alkylating agent cyclophosphamide (CTX) has been included in various chemoimmunotherapy regimens because of its well-known immunostimulatory effects. Paradoxically, cyclophosphamide can also induce suppressor cells that inhibit immune responses. However, the identity and biologic relevance of these suppressor cells are poorly defined. Here we report that cyclophosphamide treatment drives the expansion of inflammatory monocytic myeloid cells (CD11bLy6ChiCCR2hi) that possess immunosuppressive activities. In mice with advanced lymphoma, adoptive transfer (AT) of tumor-specific CD4 T cells following cyclophosphamide treatment (CTXCD4 AT) provoked a robust initial antitumor immune response, but also resulted in enhanced expansion of monocytic myeloid cells. These therapy-induced monocytes inhibited long-term tumor control and allowed subsequent relapse by mediating functional tolerization of antitumor CD4 effector cells through the PD-1-PD-L1 axis. PD-1/PD-L1 blockade after CTXCD4 AT therapy led to persistence of CD4 effector cells and durable antitumor effects. Depleting proliferative monocytes by administering low-dose gemcitabine effectively prevented tumor recurrence after CTXCD4 AT therapy. Similarly, targeting inflammatory monocytes by disrupting the CCR2 signaling pathway markedly potentiated the efficacy of cyclophosphamide- based therapy. Besides cyclophosphamide, we found that melphalan and doxorubicin can also induce monocytic myeloid suppressor cells. These findings reveal a counter-regulation mechanism elicited by certain chemotherapeutic agents and highlight the importance of overcoming this barrier to prevent late tumor relapse after chemoimmunotherapy. Cancer Res; 74(13); 3441-53.

Original languageEnglish (US)
Pages (from-to)3441-3453
Number of pages13
JournalCancer Research
Volume74
Issue number13
DOIs
StatePublished - Jul 1 2014

Fingerprint

Myeloid Cells
Immunosuppressive Agents
Cyclophosphamide
Drug Therapy
Adoptive Transfer
Neoplasms
Monocytes
Therapeutics
gemcitabine
Recurrence
Melphalan
Alkylating Agents
Immunotherapy
Doxorubicin
Lymphoma
T-Lymphocytes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor cd4 t-cell responses through the PD-1-PD-L1 axis. / Ding, Zhi Chun; Lu, Xiaoyun; Yu, Miao; Lemos, Henrique; Huang, Lei; Chandler, Phillip; Liu, Kebin; Walters, Matthew; Krasinski, Antoni; Mack, Matthias; Blazar, Bruce R.; Mellor, Andrew L.; Munn, David H.; Zhou, Gang.

In: Cancer Research, Vol. 74, No. 13, 01.07.2014, p. 3441-3453.

Research output: Contribution to journalArticle

Ding, ZC, Lu, X, Yu, M, Lemos, H, Huang, L, Chandler, P, Liu, K, Walters, M, Krasinski, A, Mack, M, Blazar, BR, Mellor, AL, Munn, DH & Zhou, G 2014, 'Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor cd4 t-cell responses through the PD-1-PD-L1 axis', Cancer Research, vol. 74, no. 13, pp. 3441-3453. https://doi.org/10.1158/0008-5472.CAN-13-3596
Ding, Zhi Chun ; Lu, Xiaoyun ; Yu, Miao ; Lemos, Henrique ; Huang, Lei ; Chandler, Phillip ; Liu, Kebin ; Walters, Matthew ; Krasinski, Antoni ; Mack, Matthias ; Blazar, Bruce R. ; Mellor, Andrew L. ; Munn, David H. ; Zhou, Gang. / Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor cd4 t-cell responses through the PD-1-PD-L1 axis. In: Cancer Research. 2014 ; Vol. 74, No. 13. pp. 3441-3453.
@article{b72c8caeaebf489c9721e1b57381a04d,
title = "Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor cd4 t-cell responses through the PD-1-PD-L1 axis",
abstract = "In recent years, immune-based therapies have become an increasingly attractive treatment option for patients with cancer. Cancer immunotherapy is often used in combination with conventional chemotherapy for synergistic effects. The alkylating agent cyclophosphamide (CTX) has been included in various chemoimmunotherapy regimens because of its well-known immunostimulatory effects. Paradoxically, cyclophosphamide can also induce suppressor cells that inhibit immune responses. However, the identity and biologic relevance of these suppressor cells are poorly defined. Here we report that cyclophosphamide treatment drives the expansion of inflammatory monocytic myeloid cells (CD11bLy6ChiCCR2hi) that possess immunosuppressive activities. In mice with advanced lymphoma, adoptive transfer (AT) of tumor-specific CD4 T cells following cyclophosphamide treatment (CTXCD4 AT) provoked a robust initial antitumor immune response, but also resulted in enhanced expansion of monocytic myeloid cells. These therapy-induced monocytes inhibited long-term tumor control and allowed subsequent relapse by mediating functional tolerization of antitumor CD4 effector cells through the PD-1-PD-L1 axis. PD-1/PD-L1 blockade after CTXCD4 AT therapy led to persistence of CD4 effector cells and durable antitumor effects. Depleting proliferative monocytes by administering low-dose gemcitabine effectively prevented tumor recurrence after CTXCD4 AT therapy. Similarly, targeting inflammatory monocytes by disrupting the CCR2 signaling pathway markedly potentiated the efficacy of cyclophosphamide- based therapy. Besides cyclophosphamide, we found that melphalan and doxorubicin can also induce monocytic myeloid suppressor cells. These findings reveal a counter-regulation mechanism elicited by certain chemotherapeutic agents and highlight the importance of overcoming this barrier to prevent late tumor relapse after chemoimmunotherapy. Cancer Res; 74(13); 3441-53.",
author = "Ding, {Zhi Chun} and Xiaoyun Lu and Miao Yu and Henrique Lemos and Lei Huang and Phillip Chandler and Kebin Liu and Matthew Walters and Antoni Krasinski and Matthias Mack and Blazar, {Bruce R.} and Mellor, {Andrew L.} and Munn, {David H.} and Gang Zhou",
year = "2014",
month = "7",
day = "1",
doi = "10.1158/0008-5472.CAN-13-3596",
language = "English (US)",
volume = "74",
pages = "3441--3453",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor cd4 t-cell responses through the PD-1-PD-L1 axis

AU - Ding, Zhi Chun

AU - Lu, Xiaoyun

AU - Yu, Miao

AU - Lemos, Henrique

AU - Huang, Lei

AU - Chandler, Phillip

AU - Liu, Kebin

AU - Walters, Matthew

AU - Krasinski, Antoni

AU - Mack, Matthias

AU - Blazar, Bruce R.

AU - Mellor, Andrew L.

AU - Munn, David H.

AU - Zhou, Gang

PY - 2014/7/1

Y1 - 2014/7/1

N2 - In recent years, immune-based therapies have become an increasingly attractive treatment option for patients with cancer. Cancer immunotherapy is often used in combination with conventional chemotherapy for synergistic effects. The alkylating agent cyclophosphamide (CTX) has been included in various chemoimmunotherapy regimens because of its well-known immunostimulatory effects. Paradoxically, cyclophosphamide can also induce suppressor cells that inhibit immune responses. However, the identity and biologic relevance of these suppressor cells are poorly defined. Here we report that cyclophosphamide treatment drives the expansion of inflammatory monocytic myeloid cells (CD11bLy6ChiCCR2hi) that possess immunosuppressive activities. In mice with advanced lymphoma, adoptive transfer (AT) of tumor-specific CD4 T cells following cyclophosphamide treatment (CTXCD4 AT) provoked a robust initial antitumor immune response, but also resulted in enhanced expansion of monocytic myeloid cells. These therapy-induced monocytes inhibited long-term tumor control and allowed subsequent relapse by mediating functional tolerization of antitumor CD4 effector cells through the PD-1-PD-L1 axis. PD-1/PD-L1 blockade after CTXCD4 AT therapy led to persistence of CD4 effector cells and durable antitumor effects. Depleting proliferative monocytes by administering low-dose gemcitabine effectively prevented tumor recurrence after CTXCD4 AT therapy. Similarly, targeting inflammatory monocytes by disrupting the CCR2 signaling pathway markedly potentiated the efficacy of cyclophosphamide- based therapy. Besides cyclophosphamide, we found that melphalan and doxorubicin can also induce monocytic myeloid suppressor cells. These findings reveal a counter-regulation mechanism elicited by certain chemotherapeutic agents and highlight the importance of overcoming this barrier to prevent late tumor relapse after chemoimmunotherapy. Cancer Res; 74(13); 3441-53.

AB - In recent years, immune-based therapies have become an increasingly attractive treatment option for patients with cancer. Cancer immunotherapy is often used in combination with conventional chemotherapy for synergistic effects. The alkylating agent cyclophosphamide (CTX) has been included in various chemoimmunotherapy regimens because of its well-known immunostimulatory effects. Paradoxically, cyclophosphamide can also induce suppressor cells that inhibit immune responses. However, the identity and biologic relevance of these suppressor cells are poorly defined. Here we report that cyclophosphamide treatment drives the expansion of inflammatory monocytic myeloid cells (CD11bLy6ChiCCR2hi) that possess immunosuppressive activities. In mice with advanced lymphoma, adoptive transfer (AT) of tumor-specific CD4 T cells following cyclophosphamide treatment (CTXCD4 AT) provoked a robust initial antitumor immune response, but also resulted in enhanced expansion of monocytic myeloid cells. These therapy-induced monocytes inhibited long-term tumor control and allowed subsequent relapse by mediating functional tolerization of antitumor CD4 effector cells through the PD-1-PD-L1 axis. PD-1/PD-L1 blockade after CTXCD4 AT therapy led to persistence of CD4 effector cells and durable antitumor effects. Depleting proliferative monocytes by administering low-dose gemcitabine effectively prevented tumor recurrence after CTXCD4 AT therapy. Similarly, targeting inflammatory monocytes by disrupting the CCR2 signaling pathway markedly potentiated the efficacy of cyclophosphamide- based therapy. Besides cyclophosphamide, we found that melphalan and doxorubicin can also induce monocytic myeloid suppressor cells. These findings reveal a counter-regulation mechanism elicited by certain chemotherapeutic agents and highlight the importance of overcoming this barrier to prevent late tumor relapse after chemoimmunotherapy. Cancer Res; 74(13); 3441-53.

UR - http://www.scopus.com/inward/record.url?scp=84903990337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903990337&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-13-3596

DO - 10.1158/0008-5472.CAN-13-3596

M3 - Article

C2 - 24780756

AN - SCOPUS:84903990337

VL - 74

SP - 3441

EP - 3453

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 13

ER -